Table 2.
IHC analysis of DLBCL cases.
| Immunohistochemical Staining | In TILs | In Tumor cells | ||||||
|---|---|---|---|---|---|---|---|---|
| The expression in TILs | Scoring situation | The expression in Tumor cells | Scoring situation | |||||
| (N=174) | positive(>0 score) | negative(0 score) | Low expression(0-3 score) | High expression(4-9 score) | positive(>0 score) | negative(0 score) | Low expression(0-3 score) | High expression(4-9 score) |
| PD-1 | (138) 79.3% | (36) 20.7% | (112)64.4% | (62) 35.6% | (7) 4.0% | (167) 96.0% | ||
| LAG-3 | (137)78.8% | (37) 21.2% | (108) 62.1% | (66)37.9% | (5)2.9% | (169 )97.1% | ||
| TIM-3 | (109) 62.7% | (65)37.3% | (135)77.6% | (39) 22.4% | (78 )44.8% | (96) 55.2% | (157) 90.2% | (17) 9.8% |
| TIGIT | (121)69.5% | (53) 30.5% | (107 )61.5% | (67)38.5% | (79)45.4% | (95) 54.6% | (161) 92.5% | (13) 7.5% |
Scoring situation of PD-1 and LAG-3 are not included in the table due to too few positive expression cases in tumor cells.